Eli Lilly ($LLY) has been doubling down on its efforts to invent new animal vaccines–opening a 48,000-square-foot research facility near its Indianapolis headquarters, for example, that its animal health division, Elanco, will use for R&D. On the production-animal side of the business, Elanco’s bread and butter until now has been cattle and swine products, but the company is looking to expand into a rapidly growing corner of food production where it has had virtually no presence: aquaculture.
{iframe}http://www.fiercepharma.com/node/350656?mkt_tok=eyJpIjoiWVdOalpUVXlaR1l4T0RNMSIsInQiOiJmcXN2T21XRzFZenFKTCtFRE5ZOEJTdkF2ZUhCZkJKY3FcL01La3k1b3JvVHB1Y0owaHhtNDFFRlJUZXRuMEZSSW5QZnNRcnNmQVN1VWxHdjVyaGEwTVpkNW1yZXpWQzNpXC9UcEExc3VHU2xRPSJ9&mrkid=730407&utm_medium=nl&utm_source=internal{/iframe}